TB Archives – Page 26 of 47 – Treatment Action Group

Exploring the Implications of the Delamanid Phase III and STREAM Trial Results

December 15, 2017
Chad Cipiti

Note that the following PDFs listed at the top of this page were handouts shared with the Webinar: --Phase III Clinical Trial Results at the 48th Union World Conference on Lung Health: Implications for the Field1, PDF --TB CAB's Proposed…

2017 Symposium: Reframing Risk and Accountability for Action to ZERO TB

December 14, 2017
Chad Cipiti

On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health. Introduction -…

TAG Statement to Human Rights Council on Human Rights Concerns in the UAE

December 13, 2017
Chad Cipiti

TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).

Remarks by Erica Lessem on TB research at the WHO Global Ministerial Conference on Ending TB

November 27, 2017
Chad Cipiti

Remarks by Erica Lessem, Deputy Executive Director – TB Project Global Ministerial Conference on Ending TB in the Sustainable Development Era Moscow, Russian Federation November 17, 2017 Using lessons learnt from HIV, how do you see civil society and advocacy…

Higher Funding for TB Research Signals Hope, but Governments Must Dramatically Increase Spending to End TB

November 8, 2017
Chad Cipiti

Global funding for tuberculosis (TB) research reached a previously unreported high of $726 million in 2016, according to a report released today by Treatment Action Group (TAG) and the United Nations–hosted Stop TB Partnership.

2017 Report on TB Research Funding Trends

November 2, 2017
Chad Cipiti

The world spent $726 million on tuberculosis (TB) research in 2016, marking the first time annual spending has exceeded $700 million since TAG began tracking funding in 2005. Although this figure is $105 million above 2015 levels, it remains woefully inadequate when judged against the innovation gaps holding back the TB response and the ambitious global goals to end the TB epidemic by 2030.

US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation

October 27, 2017
Chad Cipiti

TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.

Tools to Help Support Activists in Engaging National Policy Makers on TB

October 14, 2017
Chad Cipiti

The United Nations High Level Meeting (HLM) on TB is rapidly approaching. The U.N. HLM on TB will take place on September 26, 2018 during the second day of general debate of the General Assembly at its seventy-third session…

Expanding the Use of the TB LAM Test for People with HIV

October 3, 2017
Dorrit Walsh

TAG and partners hosted this webinar on October 3, 2017. Speakers included Lynette Mabote, AIDS & Rights Alliance for Southern Africa; Lindiwe Mvusi, Department of Health, Republic of South Africa; Stephen Wanjala, MSF; and Wayne van Gemert, Global Drug Facility.…

TAG Letter to House E&C Committee Opposing “Right to Try” Bills

October 3, 2017
Chad Cipiti

TAG’s comments to the Health Subcommittee of the U.S. House of Representatives Energy and Commerce Committee, in association with its hearing, “Examining Patient Access to Investigational Drugs,” and the deliberations of H.R. 1020, the Compassionate Freedom of Choice Act of 2017, and S. 204, the Right to Try Act of 2017.